Skip to Main Content

Paper Details

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
14
2021
AKT kinase, ER, ER+, ER-positive metastatic breast cancer, ESR1, MBC, MBC) tumors, PIK3CA, PTEN, PTEN mutations, PTEN protein, PTEN-mutant, PTEN-mutant ER+ MBC, Plasma, TP53, capivasertib, diarrhea, fulvestrant, maculopapular rash, metastatic breast cancer (, patients, tumor, tumor-suppressor gene
Author NameAffiliation
Funda Meric-BernstamMD Anderson Cancer Center
José BaselgaMemorial Sloan Kettering Cancer Center
José Baselga
  • 1 - 3

Datasets

Release 1.2